Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Genelux Corporation

GNLX ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.98

▼ -4.35%

Market Cap $89.59M · Vol 149.82K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$89.59M

Micro Cap

Div Yield

N/A

EPS Growth

+6.28%

YoY

RSI (14)

26.98

Momentum

Beta

0.59

vs Market

52W High

$8.54

75.75% below

52W Low

$1.96

2.48% above

Volume

149.82K

Avg 73.43K

P/B

14.24

Price-to-book

ROE

N/A

Return on equity

Free Float

87.13%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Genelux Corporation (GNLX) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does GNLX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-20.16%

-24.14%

-33.11%

-22.05%

YTD

-54.59%

-68.62%

-89.80%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$8.00K
Net Income	$-32,145,000.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-415,175.00%
Net Profit Margin	-401,812.50%
ROE	N/A
ROA · ROIC	-119.62% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	20,261.21
P/B	14.24
P/FCF	N/A
EPS Growth	+6.28%
Outstanding Shares	45.25M

Technical Indicators

50-Day SMA	$2.54
200-Day SMA	$2.72
RSI (14)	26.98
Beta	0.59
52-Week High	$8.54
52-Week Low	$1.96

Volume Today	149.82K
Avg Daily Volume (30D)	73.43K
Relative Volume	2.04x
Volatility (10D)	106.42
Volatility (30D)	73.62
Free Float	87.13%

Analyst Consensus

BUY

Current Price $1.98

Mean Target $19.00

52W Low$1.96 52W High$8.54

Current

Target

$1.96 $8.54

Current Analyst target

+859.60% upside potential · 5 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG0044BNBY5

ISINUS36870H1032

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -6.02% ARGX.BR argenx SE -0.41% ARGX argenx SE -1.61% GMAB.CO Genmab A/S +1.30% GMAB Genmab A/S +1.09%

Company Profile

Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.